KK

Ketki Kulkarni

Active Director Director DIN 06465711
DIN 06465711 First appointment Jan 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2013
Shareholding value •••• Premium profile

About Ketki Kulkarni

Data last updated:

Ketki Kulkarni is a Director at Saphire Biotech Private Limited (since 2013). The company operates in Pharma. Saphire Biotech Private Limited reported revenue of ₹2.36 Cr (FY 2024).

DIN 06465711
Primary Designation Director
Industry Pharma
First Appointment 07 Jan 2013
Oldest Company Age 21 yrs
Largest company Saphire Biotech Private Limited · ₹2.36 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Saphire Biotech Private Limited U24246MP2004PTC017081
Director07 Jan 20132004₹2.36 Cr (FY 2024)Active

Board colleagues of Ketki Kulkarni

Directorship timeline

Open interactive timeline →
Saphire Biotech Private Limited
Premium access

Shareholding and investment profile for Ketki Kulkarni

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ketki Kulkarni

Ketki Kulkarni currently holds 1 directorship: Saphire Biotech Private Limited (Director, since 07 Jan 2013, revenue ₹2.36 Cr (FY 2024)).

Ketki Kulkarni was first appointed on 07 Jan 2013 as Director at Saphire Biotech Private Limited.

The current boards of Ketki Kulkarni's companies include Hemant Kulkarni (Saphire Biotech Private Limited), Mihir Kulkarni (Saphire Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available